GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year https://www.bakersfield.com/ap/news/genetype-clinicians-adoption-growing---sales-up-5-fold-year-on-year/article_ebccdf40-3b03-5dba-86dc-e1a9f8cbe660.html?utm_medium=social&utm_source=twitter&utm_campaign=user-share via @Bakersfieldcali
MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the company’s latest milestones along with our clinical adoption of the Company’s groundbreaking geneType Risk Assessment Tests routinely across 12 states in the United States and nationally in Australia.The geneType team has achieved clinical proof of concept in key markets including general practice, oncology, and gynecology with repeat sales in each of these markets.
- Forums
- ASX - By Stock
- GTG
- Pioneering Genomics for Health and Wellness
Pioneering Genomics for Health and Wellness, page-34
-
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GTG (ASX) to my watchlist
|
|||||
Last
4.4¢ |
Change
0.005(12.8%) |
Mkt cap ! $6.398M |
Open | High | Low | Value | Volume |
4.1¢ | 4.4¢ | 4.1¢ | $968 | 22.13K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 22114 | 4.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.4¢ | 99910 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 22114 | 0.041 |
1 | 12500 | 0.040 |
2 | 35742 | 0.039 |
4 | 381966 | 0.038 |
5 | 194000 | 0.037 |
Price($) | Vol. | No. |
---|---|---|
0.044 | 99910 | 1 |
0.045 | 79147 | 2 |
0.050 | 1250 | 1 |
0.058 | 377358 | 1 |
0.059 | 35590 | 1 |
Last trade - 14.40pm 02/09/2024 (20 minute delay) ? |
Featured News
GTG (ASX) Chart |